23 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
14 May 24
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
8:03am
, a next-generation GABA-aminotransferase inhibitor for the potential treatment of chronic and acute seizures. Both programs are anticipated to have … milestones this year and supportive preclinical findings.
Oral formulation
◦An oral formulation of OV329 for the potential treatment of chronic seizures
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
8 Mar 24
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
8:20am
treatment of chronic seizures is being actively evaluated in a Phase 1 safety study, which includes surrogate biomarkers to measure target engagement
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
3 Nov 23
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
8:10am
study in the second half of 2024.
Ovid is expanding OV329’s development to include both oral and IV formulations for the potential treatment of chronic
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
2 Oct 23
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
12:15pm
and administrations that would make it possible to pursue both chronic and acute epilepsies; the potential development and therapeutic opportunity of OV888 (GV101 … -aminotransferase inhibitor In-licensed from: GABA-aminotransferase inhibitor In-licensed from Oral formulation for chronic epilepsies (conditions with focal
8-K
EX-99.1
za1w9
8 Nov 22
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
8:41am
8-K
EX-99.1
zv3z ewhe1end
9 Aug 22
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
8:18am
8-K
EX-99.1
v7462h v80z8x0
3 Jan 22
Entry into a Material Definitive Agreement
7:00am
8-K
EX-99.1
6d66j2r 0kh
22 Oct 20
Regulation FD Disclosure
1:14pm
424B5
lt8v5lqni92qr5c
26 Aug 20
Prospectus supplement for primary offering
4:07pm
424B5
xd0l4tygpdl3b
7 Oct 19
Prospectus supplement for primary offering
9:35pm
424B5
zxfcqfgtbjb
7 Oct 19
Prospectus supplement for primary offering
9:33pm
424B5
amserqbe3a
3 Oct 19
Prospectus supplement for primary offering
4:11pm